CA2987388A1 - Liquid formulations of celecoxib for oral administration - Google Patents
Liquid formulations of celecoxib for oral administrationInfo
- Publication number
- CA2987388A1 CA2987388A1 CA2987388A CA2987388A CA2987388A1 CA 2987388 A1 CA2987388 A1 CA 2987388A1 CA 2987388 A CA2987388 A CA 2987388A CA 2987388 A CA2987388 A CA 2987388A CA 2987388 A1 CA2987388 A1 CA 2987388A1
- Authority
- CA
- Canada
- Prior art keywords
- celecoxib
- pharmaceutical preparation
- preparation according
- liquid pharmaceutical
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title claims abstract description 126
- 229960000590 celecoxib Drugs 0.000 title claims abstract description 126
- 239000012669 liquid formulation Substances 0.000 title description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000000725 suspension Substances 0.000 claims abstract description 42
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 73
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 50
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 30
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 26
- 235000011187 glycerol Nutrition 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 18
- 229920001285 xanthan gum Polymers 0.000 claims description 18
- 239000006184 cosolvent Substances 0.000 claims description 17
- 239000004615 ingredient Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 15
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 15
- 229960003415 propylparaben Drugs 0.000 claims description 15
- 239000000230 xanthan gum Substances 0.000 claims description 15
- 235000010493 xanthan gum Nutrition 0.000 claims description 15
- 229940082509 xanthan gum Drugs 0.000 claims description 15
- 241000219095 Vitis Species 0.000 claims description 14
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 14
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 14
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 14
- 229920000053 polysorbate 80 Polymers 0.000 claims description 14
- 239000001509 sodium citrate Substances 0.000 claims description 14
- 239000004376 Sucralose Substances 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000019634 flavors Nutrition 0.000 claims description 12
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 12
- 229940068968 polysorbate 80 Drugs 0.000 claims description 12
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 12
- 235000019408 sucralose Nutrition 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 11
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 11
- 229960002216 methylparaben Drugs 0.000 claims description 11
- 229920001983 poloxamer Polymers 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 10
- 239000002736 nonionic surfactant Substances 0.000 claims description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 229960000502 poloxamer Drugs 0.000 claims description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 8
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 229960005150 glycerol Drugs 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229940038773 trisodium citrate Drugs 0.000 claims description 6
- 150000004683 dihydrates Chemical class 0.000 claims description 5
- 229960004756 ethanol Drugs 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 2
- 229940050865 sodium phosphate,monobasic,monohydrate Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 abstract description 17
- 239000008297 liquid dosage form Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 89
- 238000009472 formulation Methods 0.000 description 35
- 239000000243 solution Substances 0.000 description 34
- 229960004106 citric acid Drugs 0.000 description 12
- 229940100692 oral suspension Drugs 0.000 description 10
- 239000008213 purified water Substances 0.000 description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- 239000013011 aqueous formulation Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 229940100688 oral solution Drugs 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 229960004543 anhydrous citric acid Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- -1 diaryl substituted pyrazole Chemical compound 0.000 description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YNIRKEZIDLCCMC-UHFFFAOYSA-K trisodium;phosphate;hydrate Chemical compound [OH-].[Na+].[Na+].[Na+].OP([O-])([O-])=O YNIRKEZIDLCCMC-UHFFFAOYSA-K 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 229940047495 celebrex Drugs 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 2
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 2
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 2
- 239000008137 solubility enhancer Substances 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940009674 methylparaben / propylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168012P | 2015-05-29 | 2015-05-29 | |
| US62/168,012 | 2015-05-29 | ||
| US15/163,258 US20160346300A1 (en) | 2015-05-29 | 2016-05-24 | Liquid formulations of celecoxib for oral administration |
| PCT/US2016/033937 WO2016196085A1 (en) | 2015-05-29 | 2016-05-24 | Liquid formulations of celecoxib for oral administration |
| US15/163,258 | 2016-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2987388A1 true CA2987388A1 (en) | 2016-12-08 |
Family
ID=57396976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2987388A Abandoned CA2987388A1 (en) | 2015-05-29 | 2016-05-24 | Liquid formulations of celecoxib for oral administration |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160346300A1 (enExample) |
| EP (1) | EP3302430A4 (enExample) |
| JP (1) | JP2018516279A (enExample) |
| AU (1) | AU2016270504A1 (enExample) |
| BR (1) | BR112017025527A2 (enExample) |
| CA (1) | CA2987388A1 (enExample) |
| MX (1) | MX2017015202A (enExample) |
| RU (1) | RU2017145602A (enExample) |
| WO (1) | WO2016196085A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016191744A1 (en) * | 2015-05-28 | 2016-12-01 | Dr. Reddy's Laboratories Ltd. | Oral composition of celecoxib for treatment of pain |
| WO2022185338A1 (en) * | 2021-03-05 | 2022-09-09 | Alkem Laboratories Limited | Stable oral suspension of celecoxib and method of preparation thereof |
| CN115737554B (zh) * | 2022-11-28 | 2024-07-09 | 宜昌人福药业有限责任公司 | 一种氯巴占口服混悬剂的制备方法 |
| WO2024142089A1 (en) * | 2022-12-27 | 2024-07-04 | Cipla Limited | Injectable compositions of celecoxib |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4145440A (en) * | 1977-08-18 | 1979-03-20 | The Upjohn Company | Liquid suspension of an aluminum salt of ibuprofen |
| IN191512B (enExample) * | 2000-01-21 | 2003-12-06 | Panacea Biotech | |
| MXPA02010259A (es) * | 2000-04-18 | 2003-12-11 | Pharmacia Corp | Formulacion de accion rapida de un inhibidor selectivo de ciclooxigenasa-2. |
| AR035642A1 (es) * | 2000-05-26 | 2004-06-23 | Pharmacia Corp | Uso de una composicion de celecoxib para el alivio rapido del dolor |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
| UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
| US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| PL371133A1 (en) * | 2001-12-20 | 2005-06-13 | Pharmacia Corporation | Pharmaceutical suspension for oral administration |
| AU2003238221A1 (en) * | 2002-06-17 | 2003-12-31 | Taro Pharmaceuticals U.S.A, Inc. | Ibuprofen suspension |
| US20060148877A1 (en) * | 2002-11-26 | 2006-07-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
| US20050014729A1 (en) * | 2003-07-16 | 2005-01-20 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| US20050266031A1 (en) * | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
| US20080014274A1 (en) * | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
| US20110183944A1 (en) * | 2010-01-28 | 2011-07-28 | Paul Ashton | SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS |
| EP3530268B1 (en) * | 2012-10-09 | 2021-12-15 | Attentive Therapeutics, Inc. | Therapeutic treatment |
| CN103932977A (zh) * | 2014-04-15 | 2014-07-23 | 江苏正大清江制药有限公司 | 一种塞来昔布制剂的制备方法 |
-
2016
- 2016-05-24 WO PCT/US2016/033937 patent/WO2016196085A1/en not_active Ceased
- 2016-05-24 EP EP16804009.5A patent/EP3302430A4/en not_active Withdrawn
- 2016-05-24 US US15/163,258 patent/US20160346300A1/en not_active Abandoned
- 2016-05-24 AU AU2016270504A patent/AU2016270504A1/en not_active Abandoned
- 2016-05-24 RU RU2017145602A patent/RU2017145602A/ru not_active Application Discontinuation
- 2016-05-24 BR BR112017025527A patent/BR112017025527A2/pt not_active Application Discontinuation
- 2016-05-24 CA CA2987388A patent/CA2987388A1/en not_active Abandoned
- 2016-05-24 MX MX2017015202A patent/MX2017015202A/es unknown
- 2016-05-24 JP JP2018513730A patent/JP2018516279A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017015202A (es) | 2018-07-06 |
| RU2017145602A3 (enExample) | 2019-11-25 |
| AU2016270504A1 (en) | 2017-12-14 |
| US20160346300A1 (en) | 2016-12-01 |
| WO2016196085A1 (en) | 2016-12-08 |
| RU2017145602A (ru) | 2019-07-02 |
| JP2018516279A (ja) | 2018-06-21 |
| EP3302430A4 (en) | 2019-05-29 |
| EP3302430A1 (en) | 2018-04-11 |
| BR112017025527A2 (pt) | 2018-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW442295B (en) | Stable freeze-dried pharmaceutical composition | |
| JP5330347B2 (ja) | 安定な高濃度メロキシカム溶液 | |
| FI95773C (fi) | Menetelmä vesipitoisen, N-(3,4-dimetoksikinnamoyyli)antraniilihappoa sisältävän farmaseuttisen koostumuksen valmistamiseksi | |
| CA2645205C (en) | Stable aqueous suspension having palatable taste | |
| EP2405890B1 (en) | Riluzole aqueous suspensions | |
| US20160346300A1 (en) | Liquid formulations of celecoxib for oral administration | |
| CN1829503B (zh) | 含有氟苯尼考的兽用水性可注射悬浮液 | |
| CA3029569A1 (en) | Methods for the preparation of a levothyroxine solution | |
| US9399013B2 (en) | Stable aqueous suspension | |
| CZ20031612A3 (cs) | Farmaceutický prostředek pro parenterální podání | |
| JP2002193799A (ja) | 薬剤合成物及びその調合方法並びに治療方法 | |
| WO2023222184A1 (en) | Aqueous ticagrelor solution, method of manufacturing and uses | |
| JP2023505255A (ja) | 眼科用医薬組成物 | |
| EP1946747A1 (en) | Pharmaceutical composition of improved stability containing taxane derivatives | |
| AU2004257556C1 (en) | A stable clozapine suspension formulation | |
| JPH0536412B2 (enExample) | ||
| US20230293514A1 (en) | Injectable depot formulation comprising cariprazine free base particles | |
| EP1508332A1 (en) | Medicinal composition | |
| JP5171143B2 (ja) | 用時溶解型ビタミン製剤及びその製造方法 | |
| WO2023148763A1 (en) | Injectable pharmaceutical compositions of azole antifungal agents | |
| GB2627797A (en) | Trilostane formulation | |
| AU2015261543B2 (en) | Controlled release compositions and their methods of use | |
| US9029390B2 (en) | Oral composition containing an antiplatelet agent of the thienopyridine family in the form of free base |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220816 |
|
| FZDE | Discontinued |
Effective date: 20220816 |